Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $771.13 | 36 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $313.91 | 15 | $0 (2024) |
| Relypsa, Inc. | $125.00 | 1 | $0 (2018) |
| Allergan Inc. | $111.61 | 8 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $53.58 | 4 | $0 (2018) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $45.35 | 2 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $36.82 | 2 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $29.04 | 1 | $0 (2024) |
| HOSPIRA, INC. | $20.72 | 1 | $0 (2017) |
| Chiesi USA, Inc. | $18.16 | 1 | $0 (2019) |
| Cumberland Pharmaceuticals, Inc. | $16.94 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $260.75 | 12 | ABBVIE INC. ($194.89) |
| 2023 | $39.38 | 2 | AbbVie Inc. ($39.38) |
| 2022 | $23.01 | 1 | ABBVIE INC. ($23.01) |
| 2021 | $56.63 | 3 | AbbVie Inc. ($56.63) |
| 2019 | $62.72 | 4 | Allergan Inc. ($44.56) |
| 2018 | $254.86 | 9 | Relypsa, Inc. ($125.00) |
| 2017 | $73.78 | 5 | Allergan Inc. ($22.62) |
All Payment Transactions
36 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $29.04 | General |
| Category: CRITICAL CARE | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Food and Beverage | In-kind items and services | $18.19 | General |
| Category: Rare Disease | ||||||
| 10/01/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Food and Beverage | In-kind items and services | $12.42 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/13/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ, DALVANCE | Food and Beverage | In-kind items and services | $24.72 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/09/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $23.82 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/26/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ, DALVANCE | Food and Beverage | In-kind items and services | $32.90 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/29/2024 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Food and Beverage | In-kind items and services | $18.63 | General |
| Category: Rare Disease | ||||||
| 05/15/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ, DALVANCE | Food and Beverage | In-kind items and services | $22.57 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/29/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/20/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO | Food and Beverage | In-kind items and services | $22.87 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/13/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Food and Beverage | In-kind items and services | $23.19 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/18/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ, DALVANCE | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/11/2023 | AbbVie Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $16.17 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/23/2023 | AbbVie Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $23.21 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/16/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/30/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/15/2021 | AbbVie Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $24.51 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/18/2021 | AbbVie Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/18/2019 | Chiesi USA, Inc. | CLEVIPREX (Drug) | Food and Beverage | Cash or cash equivalent | $18.16 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/20/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $12.89 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/13/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $13.38 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/12/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/17/2018 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $11.94 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/20/2018 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $22.78 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 09/19/2018 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 132 | 477 | $238,500 | $93,850 |
| 2022 | 2 | 174 | 523 | $258,100 | $106,362 |
| 2021 | 2 | 155 | 522 | $207,400 | $108,672 |
| 2020 | 1 | 115 | 410 | $138,708 | $85,983 |
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 132 | 477 | $238,500 | $93,850 | 39.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 163 | 509 | $253,900 | $104,911 | 41.3% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2022 | 11 | 14 | $4,200 | $1,451 | 34.6% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 143 | 509 | $204,450 | $107,292 | 52.5% |
| 99292 | Critical care delivery critically ill or injured patient | Facility | 2021 | 12 | 13 | $2,950 | $1,380 | 46.8% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 115 | 410 | $138,708 | $85,983 | 62.0% |
About Sonia Choksi
Sonia Choksi is a Internal Medicine healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174635551.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Sonia Choksi has received a total of $771.13 in payments from pharmaceutical and medical device companies, with $260.75 received in 2024. These payments were reported across 36 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($771.13).
As a Medicare-enrolled provider, Choksi has provided services to 576 Medicare beneficiaries, totaling 1,932 services with total Medicare billing of $394,866. Data is available for 4 years (2020–2023), covering 6 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Bronx, NY
- Active Since 08/31/2006
- Last Updated 07/08/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1174635551
Products in Payments
- TEFLARO (Drug) $171.99
- AVYCAZ (Drug) $132.12
- Veltassa (Drug) $125.00
- DALVANCE (Drug) $121.41
- ZERBAXA (Drug) $53.58
- LifeVest (Device) $45.35
- ANDEXXA (Biological) $36.82
- TERLIVAZ (Drug) $29.04
- PRECEDEX (Drug) $20.72
- CLEVIPREX (Drug) $18.16
- Vaprisol (Drug) $16.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Bronx
Timothy Kanter, M.d, M.D
Internal Medicine — Payments: $865,160
Dr. Jason Leider, M.d, M.D
Internal Medicine — Payments: $759,257
Bulent Atac, Md, MD
Internal Medicine — Payments: $654,500
Shervin Mortazavi, M.d, M.D
Internal Medicine — Payments: $402,598
Dr. Elizabeth Jenny-Avital
Internal Medicine — Payments: $176,355
Vivek Gumaste, M.d, M.D
Internal Medicine — Payments: $163,229